Who are Pregabalin & Magnesium sulphate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gabapentin/B-complex, Naltrexone plus Gabapentin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pregabalin-magnesium-sulphate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Pregabalin & Magnesium sulphate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pregabalin & Magnesium sulphate (Pregabalin & Magnesium sulphate) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant/analgesic combination. Area: Oncology; Neurology.

phase 3 Anticonvulsant/analgesic combination Alpha-2-delta calcium channel subunit; NMDA receptor Oncology; Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Pregabalin & Magnesium sulphate (Pregabalin & Magnesium sulphate) — National Cancer Institute, Egypt. Pregabalin reduces neuronal calcium influx and neurotransmitter release while magnesium sulphate acts as an NMDA receptor antagonist, together modulating neuropathic pain and potentially chemotherapy-induced peripheral neuropathy.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pregabalin & Magnesium sulphate TARGET	Pregabalin & Magnesium sulphate	National Cancer Institute, Egypt	phase 3	Anticonvulsant/analgesic combination	Alpha-2-delta calcium channel subunit; NMDA receptor
Gabapentin/B-complex	Gabapentin/B-complex	Merck KGaA, Darmstadt, Germany	marketed	Anticonvulsant/analgesic combination with vitamin supplementation	Alpha-2-delta subunit of voltage-gated calcium channels (gabapentin component)
Naltrexone plus Gabapentin	Naltrexone plus Gabapentin	Medical University of South Carolina	phase 3	Opioid antagonist + anticonvulsant/analgesic combination	Opioid receptors (mu, delta, kappa) + voltage-gated calcium channels (Cav2.1, Cav2.2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant/analgesic combination class)

National Cancer Institute, Egypt · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pregabalin & Magnesium sulphate — Competitive Intelligence Brief. https://druglandscape.com/ci/pregabalin-magnesium-sulphate. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab